Luteolin for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Luteolin for Health & Longevity

Created on 09/15/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A plant compound from everyday vegetables and herbs, concentrated into supplement form. It quiets inflammatory signaling rather than mopping up free radicals; laboratory and animal work is extensive, human evidence thinner. Every controlled trial showing benefit paired luteolin with a second active compound. Safety looks favorable. Much of the evidence comes from parties selling luteolin. (Full Review)

Protocol

Standard supplement dose
100–500 mg daily
Purified luteolin, taken with food. Most single-ingredient capsules deliver 100 mg; registered single-agent trials used 100–600 mg daily. Adults over 65: 100–200 mg daily.
Best time of day
Morning with breakfast
The transient activation reported in the open-label trial is easier to tolerate during the day than at night.
Single versus split dosing
Split above 200 mg
Doses above 200 mg are commonly split morning and evening; the smell-recovery trials tested both once- and twice-daily schedules.
Time to effect
Smell recovery
30–90 days
Smell-recovery trials measured change at 30–90 days.
Cardiometabolic trial
6 months
The cardiometabolic trial ran six months.
Histamine-related symptoms
Days to weeks
Allergic and histamine-related symptom reports describe days to weeks, but rest on uncontrolled observation.

Benefits

Contraindications
  • Pregnancy and lactation
  • Known peanut allergy (product peanut-hull derived, not certified protein-free)
  • Premenopausal women with estrogen-dependent infertility treatment or ovulation induction under way
  • Adults on aromatase inhibitors for hormone-receptor-positive breast cancer, without oncology supervision
  • Untreated or unstable thyroid disease (thyroid-stimulating hormone above 4.5 mIU/L or below 0.4 mIU/L)
  • Child-Pugh Class B or C hepatic impairment
  • Within 14 days of planned surgery or a spinal or epidural anesthetic procedure
  • Within 12 months of coronary stent placement while on clopidogrel
    •
Key Interactions
  • Carboxylesterase 1 substrates (clopidogrel, oseltamivir, methylphenidate)
  • CYP3A4 substrates (simvastatin, atorvastatin, midazolam, cyclosporine, tacrolimus)
  • CYP1A2 substrates (theophylline, tizanidine, clozapine, caffeine)
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)
  • Levothyroxine and antithyroid drugs (methimazole, propylthiouracil)
  • Estrogen therapy (estradiol, conjugated estrogens)
  • Glucose-lowering agents (metformin, glipizide, insulin, semaglutide)
  • Antihypertensives (lisinopril, amlodipine, losartan)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin)
  • Over-the-counter antihistamines (cetirizine, loratadine, famotidine)
  • Flavonoid supplements (quercetin, fisetin, apigenin, epigallocatechin gallate)
  • Blood-glucose-lowering supplements (berberine, chromium, alpha-lipoic acid)
  • Blood-pressure-lowering supplements (beetroot nitrate, magnesium, fish oil)
  • Non-heme iron absorption
  • Senolytic regimens (dasatinib with quercetin, fisetin) and chemotherapy (doxorubicin, cisplatin)
    •

Risk & Side Effects

  • Low: Transient irritability and behavioral activation
    •
  • Speculative: Gastrointestinal upset at higher doses; suppression of estrogen production; reduced thyroid iodide uptake; interference with drug-activating and drug-clearing enzymes; loss of effect or reversal at high doses; platelet inhibition and bleeding tendency; allergen carry-over from peanut-shell extracts
    •

Monitoring

Marker Target Why
High-sensitivity C-reactive protein < 1.0 mg/L Primary target; identifies whether inflammation exists to suppress
HbA1c 4.8–5.4% Tracks the glucose endpoint that changed in the metabolic trial
Fasting insulin 2–5 µIU/mL Detects insulin resistance earlier than glucose does
Alanine aminotransferase < 20 U/L (women), < 25 U/L (men) Liver enzyme; both an outcome and a safety check
Thyroid-stimulating hormone 0.5–2.0 mIU/L Safety check for the reduced iodide uptake seen in thyroid cells
Free thyroxine 1.0–1.5 ng/dL Confirms whether a thyroid-stimulating hormone shift reflects real hormone change
Estradiol (premenopausal women) Cycle-dependent; track change from own baseline, same cycle day Safety check for the aromatase suppression seen in cell studies
Estimated glomerular filtration rate > 90 mL/min/1.73 m² Kidney function; guides dose reduction in older adults
Serum tryptase 2–8 ng/mL Baseline mast-cell activity where histamine symptoms are the reason for use

Cadence: Baseline panel before starting; thyroid-stimulating hormone and estradiol recheck at three months; full repeat of the inflammatory, metabolic and liver panel at six months; annually thereafter while use continues.

Qualitative Assessment

  • Smell acuity, tracked against a fixed set of familiar odours rather than by impression
  • Frequency and intensity of histamine-related symptoms such as flushing, itch and nasal congestion
  • Mental clarity and the ability to sustain concentration through a working day
  • Joint and muscle stiffness on waking
  • Sleep onset latency, which detects the interaction with unchanged caffeine intake
  • Exercise recovery and perceived effort during repeated high-intensity efforts
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.